Quelle est la capitalisation boursière pour China Resources Boya Bio-pharmaceutical Group Co., Ltd. (300294)

La capitalisation boursière pour China Resources Boya Bio-pharmaceutical Group Co., Ltd. (300294) est $1.09B

China Resources Boya Bio-pharmaceutical Group Co., Ltd. (300294) Divisions d'Actions

Q: Quel est le prix pour China Resources Boya Bio-pharmaceutical Group Co., Ltd. (300294)

Le prix pour China Resources Boya Bio-pharmaceutical Group Co., Ltd. (300294) est $2.16

Established in 1993 and headquartered in Fuzhou, China, China Resources Boya Bio-pharmaceutical Group Co., Ltd. (formerly Boya Bio-pharmaceutical Group Co., Ltd.) is a comprehensive pharmaceutical enterprise operating across China. The company is engaged in the research, development, production, and sale of a diverse portfolio, primarily focusing on blood products, diabetes medications, and various biochemical and chemical pharmaceuticals. Its extensive range of blood-derived products includes human fibrinogen, human albumin, intravenous human immunoglobulin, rabies immunoglobulin, hepatitis B human immunoglobulin, and freeze-dried intravenous human immunoglobulin. For diabetes management, the company offers metformin hydrochloride (both tablets and enteric-coated versions), pioglitazone hydrochloride dispersible tablets, glimepiride tablets, and calcium dobesilate capsules. Additionally, it produces specialized injections such as compound osteotide, oxytocin, and heparin sodium, which are utilized across numerous medical fields, including general medicine, hepatitis treatment, gynecology, and immunomodulatory applications.